Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPABAY: Elimusertib and Copanlisib in Advanced Solid Tumors
NCT05010096Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of elimusertib in solid tumor (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events (AEs) and Incidence of dose limiting toxicities (DLTs) up to 28 days. Planned start Mar 2022; status: withdrawn.
02
Drugs
elimusertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05010096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05010096.